Security key
Y1R80M106
CytoMed Therapeutics Ltd - Ordinary Shares (GDTC)
CUSIP: Y1R80M106
Q2 2023 13F Holders as of 30 Jun 2023
- Security type / class
- Equity / Ordinary Shares
- Total 13F shares
- 54
- Total 13F value
- $165
- Share change
- +54
- SEC-reported price per share
- $3.06
- Number of holders
- 1
- Value change
- +$165
- Number of buys
- 1
- Shares outstanding
- 11,735,810
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2023
Institutions
1
Top holders
1
GDTC full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2023
CytoMed Therapeutics Ltd SEC filings
CytoMed Therapeutics Ltd company facts
Broader feeds
Reporting periods
Holder history for CUSIP Y1R80M106
Recent filing periods:
Ownership snapshot
Top reported holders of GDTC - CytoMed Therapeutics Ltd - Ordinary Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Glorious Finance Ltd
Disclosed value leader
—
Comparable rows
0/4
Latest evidence
31 Mar 2023
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
4 rows are not safely comparable across share classes.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 4 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Glorious Finance Ltd's linked filing trail.
Detailed SEC evidence table Showing 1-4 of 4 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Glorious Finance Ltd |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
4,653,604 shares
|
— | 31 Mar 2023 |
| Shu Wang |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
883,858 shares
|
— | 31 Mar 2023 |
| Jieming Zeng |
3/4/5
CSO and CMO, Director
|
—
class O/S missing
|
—
589,239 shares
|
— | 31 Mar 2023 |
| Lucas Tien Wee Luk |
3/4/5
Chief Clinical Officer, Director
|
—
class O/S missing
|
—
92,563 shares
|
— | 31 Mar 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
54
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2023 vs Q4 2025 Across Filers
Q4 2025 holders
5
Q2 2023 holders
1
Holder diff
-4
| Investor | Q4 2025 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend